ZoetisMEX:ZTS 71 EBITDA Margin % is 41.51% as of Mar. 2026, which is 3% above its 10-year median of 40.31. GuruFocus rates MEX:ZTS with a GF Score™ of 71/100 and a GF Value™ of MXN3,418.50 (Significantly Undervalued). Among 955 Drug Manufacturers companies, Zoetis ranks better than 94.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zoetis's EBITDA for the
three
months ended in Mar. 2026 was MXN16,933 Mil. Zoetis's Revenue for the
three
months ended in Mar. 2026 was MXN40,790 Mil. Therefore, Zoetis's EBITDA margin for the quarter that ended in Mar. 2026 was 41.51%.
Zoetis (MEX:ZTS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zoetis EBITDA Margin % Related Terms
Zoetis EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zoetis's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ZTS vs UTHR, VTRS, NBIX: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zoetis's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (MEX:ZTS) has a EBITDA Margin % of 41.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zoetis and its competitors. This is near median its historical median of 40.31. Over the past decade, Zoetis' EBITDA Margin % has ranged from 33.43 to 42.98. According to the industry distribution chart, Zoetis ranks #49 out of 955 companies in the Drug Manufacturers industry, placing it in the top 5.1%.
Is Zoetis' EBITDA Margin % too high?
Zoetis' current EBITDA Margin % of 41.51% is near median its 10-year median of 40.31. Over the past 10 years, this metric has ranged from a low of 33.43 to a high of 42.98. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Zoetis' value of 41.51% is 233.7% above this industry median. Based on the distribution chart, Zoetis ranks #49 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zoetis has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' EBITDA Margin % compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #49 out of 955 companies for EBITDA Margin %. This places Zoetis in the top 5% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Zoetis' value of 41.51% is 233.7% above this benchmark. Historically, Zoetis' own EBITDA Margin % has ranged from 33.43 to 42.98 over the past decade. While the company's 10-year median is 40.31 vs. the industry median of 12.44, Zoetis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current EBITDA Margin % of 41.51% is 233.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current EBITDA Margin % is 41.51%, which is near median its own 10-year median of 40.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (MEX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN3,418.50, compared to a current price of MXN1,371.70 — trading 59.9% below its estimated fair value. The current EBITDA Margin % is 41.51%, which is near median its 10-year median of 40.31 and 233.7% above the Drug Manufacturers industry median of 12.44. Zoetis' overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zoetis (MEX:ZTS), the current EBITDA Margin % is 41.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (MEX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of MXN1,371.70 is trading 59.9% below its estimated GF Value™ of MXN3,418.50.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for MEX:ZTS:
EBITDA Margin %: 41.51% (near median its 10-year median of 40.31)
GF Value™: MXN3,418.50 vs. price of MXN1,371.70 (59.9% below fair value)
Industry Position: 233.7% above the Drug Manufacturers median (#49 of 955)
No single metric tells the full story. See the MEX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
71GF Score
Get the complete analysis for MEX:ZTS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ZTS has been successfully added to your 
